Health 2035 Summit: Roivant CEO Matt Gline on why he believes this is a good time to be hunting for assets on the shelves of big pharma, and upcoming catalysts

blonca9
Aug 27, 2024
1 min read

He describes why this may be a good time to asset hunt, but also why Roivant has been conservative with its cash. Plus upcoming catalysts in FcRN, TYK2xJAK1, GM-CSF, and more.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Health 2035 Summit: Roivant CEO Matt Gline on why he believes this is a good time to be hunting for assets on the shelves of big pharma, and upcoming catalysts

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight